X
Pharma Advancement
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

    Clinical Development

    AI Revolutionizing Drug Discovery and Clinical Development

    Drug-Development

    China’s Super Me-Too Drug Development: A New Pharma Frontier

    Omics Based Clinical Trials

    Asia Pacific Omics-Based Clinical Trials Market Growth

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

    Clinical Development

    AI Revolutionizing Drug Discovery and Clinical Development

    Drug-Development

    China’s Super Me-Too Drug Development: A New Pharma Frontier

    Omics Based Clinical Trials

    Asia Pacific Omics-Based Clinical Trials Market Growth

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home News

Future Biotech Platforms Likely To Depend Primarily On Urine

Content Team by Content Team
13th December 2022
in News, Research & Development

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

A mechanism that employs urea to begin the manufacturing of proteins in the massive amounts required by the biotech industry has been developed by researchers at the Universities of Birmingham and Aston.

Typically, in this procedure, little DNA fragments are added to bacteria like E.coli to induce them to overproduce particular proteins. It was initially developed in the 1970s and is now a well-known technology. However, inducer molecules, which can be expensive and frequently require special management, like refrigeration—typically cause overproduction.

The researchers have created a process that is less complicated, more affordable, and employs components that are readily available by substituting urea.

The scientists looked at both refined urea and the urea included in typical garden fertilisers in a recent study that was published in the journal New Biotechnology. They demonstrated that any source could produce results that were comparable.

Their objective is to make this technology accessible to biotech companies that want to investigate how to maximise their operations while also keeping their costs down, according to co-author and professor Steve Busby of the University of Birmingham’s School of Biosciences.

The scientists also demonstrated that by adjusting the doses used, it was feasible to precisely control the levels of protein induced by the urea molecule. To prevent hurting or wearing out the host microorganisms, it’s crucial to do this. They discovered it was possible to maximise output to levels comparable to those generated with medium-strength promoters, which are currently the norm in the biotech sector.

The research expands on previous work in which the scientists showed that nitrate, a readily available, affordable, and stable inorganic ion, may also be employed as a trigger. Since nitrate is frequently included in many commercial fertilisers and even some garden fertilisers, it is constantly accessible, even in places where other types of promoter chemicals would not be.

The School of Biosciences’ Dr. Joanne Hothersall, who is a co-author on the paper, said that both urea and nitrate will become much more easily accessible and easier to use in regions where infrastructure prevents access, for example when sustaining a cold supply chain is difficult. They anticipate that these novel methodologies will present fresh research opportunities for the biotech sector.

The Biotechnology and Biological Sciences Research Council, a division of UK research and innovation, provided funding for the study.

Previous Post

NICE Methodology Raises Concerns For Kidney Research UK

Next Post

Canadian And US Developers To Test Psychedelic Drugs In UK

Related Posts

WuXi Biologics and Virogen Bio partner to advance VG712
News

WuXi Biologics and Virogen Bio partner to advance VG712

19th June 2025
Construction of WuXi Biologics Microbial Manufacturing Site
News

Construction of WuXi Biologics Microbial Manufacturing Site

19th June 2025
Beyfortus From Sanofi to Make Imprint in 2025 26 RSV Season
News

Beyfortus From Sanofi to Make Imprint in 2025-26 RSV Season

19th June 2025
Thermo-Fischer-Accelerator Drug Development an Ideal Choice
News

Thermo Fischer Accelerator Drug Development an Ideal Choice

19th June 2025
IQVIA Custom Built AI Agents for Life Sciences Healthcare
News

IQVIA Custom-Built AI Agents for Life Sciences, Healthcare

19th June 2025
SCHOTT Pharma Invests
News

SCHOTT Pharma Invests EUR 100 Million in RTU Cartridges

9th June 2025
Next Post

Canadian And US Developers To Test Psychedelic Drugs In UK

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In